Physician profile
Bryan Heath
NPI 1528091725
$5,045.88
in general payments reported to CMS, 2019-2025
27 companies · $638 in 2025
The $638 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $521 · 2021: $545 · 2022: $610 · 2023: $457 · 2024: $1,150 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,288.74 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $643.76 | 2024-2025 | Voquezna |
| Celgene Corporation | $528.12 | 2019-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $368.49 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.17 | 2019-2023 | Trulance |
| Janssen Biotech, INC. | $285.66 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $242.36 | 2019-2025 | |
| Madrigal Pharmaceuticals | $206.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $179.33 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $167.58 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $135.68 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.36 | 2019 | |
| Vivus LLC | $82.29 | 2021-2024 | Qsymia |
| Braintree Laboratories, INC. | $78.79 | 2020-2023 | Sutab |
| Pentax of America, INC. | $70.88 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $65.54 | 2019 | |
| Daiichi Sankyo INC. | $53.12 | 2020-2022 | |
| Ethicon US, LLC | $36.17 | 2019-2020 | |
| Evoke Pharma, INC. | $35.63 | 2022-2023 | Gimoti |
| Redhill Biopharma INC. | $33.83 | 2020 | |
| Aimmune Therapeutics, INC. | $28.75 | 2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $27.06 | 2024-2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $21.75 | 2019 | |
| Exact Sciences Corporation | $20.73 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $13.73 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Heath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.